Similar companies
Income Statement (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Revenue | 661M | 170.8% |
| Gross Profit | 661M | 170.8% |
| Cost of Revenue | 416M | 1.3% |
| Operating expense | 3.5M | 39.5% |
| Net Income | -2.4M | 62.8% |
| EBITDA | -990,000 | 83.8% |
Balance Sheet (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Total Assets | 4.2M | 40.1% |
| Total Liabilities | 11M | 9.3% |
| Total Equity | 1.29B | 14299.8% |
| Shares Outstanding | 41M | 5.2% |
Cash Flow (USD)
| Q4 '24 | QoQ | |
|---|---|---|
| Cash from operations | -3.8M | 90.7% |
| Cash from financing | 4.2M | 141.4% |
EPS
Financial Highlights for Conduit Pharmaceuticals in Q4 '24
Conduit Pharmaceuticals reported a revenue of 661M, which is a 170.8% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 661M, marking a 170.8% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 416M, a 1.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 3.5M, showing a -39.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -2.4M, showing a 62.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -990,000, showing a 83.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Conduit Pharmaceuticals with growth in revenue, gross profit, and net income.
